PolyPid Ltd. (PYPD)
PYPDNext catalyst
D-PLEX
Prevention of surgical site infections in abdominal colorectal surgery
Get an email about PYPD's next catalysts
Track PolyPid Ltd. (PYPD) (PYPD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
PYPD Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $0.46 | FQ end Sep/2026 | Call: bmo
FDA PDUFA Date D-PLEX100
For Prevention of surgical site infections in abdominal colorectal surgery. NDA, Priority Review. Verified against the company announcement on 2026-10-16.
SourceUpcoming FDA decisions
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
D-PLEX | Phase 3 | Abdominal Surgery | - | - |
Frequently asked questions
What is in PolyPid Ltd. (PYPD)'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in PolyPid Ltd. (PYPD)'s (PYPD) pipeline across Phase 3. Its lead program is D-PLEX (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PolyPid Ltd. (PYPD)'s next FDA catalyst?→
PolyPid Ltd. (PYPD)'s (PYPD) next tracked catalyst is a PDUFA date expected Nov 28, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PYPD biotech catalysts?→
Add PYPD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PolyPid Ltd. (PYPD)'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.